866-997-4948(US-Canada Toll Free)

Tuberculosis Partnering 2007-2013

Published By :

Current Partnering

Published Date : Oct 2013

Category :

Biotechnology

No. of Pages : 100 Pages


The Tuberculosis Partnering 2007-2013 report provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.
 
  • Trends in tuberculosis partnering deals
  • Top tuberculosis deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type
 
The Tuberculosis Partnering 2007-2013 provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.
 
The report provides an analysis of tuberculosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors tuberculosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
 
This data driven report contains over 130 links to online copies of actual tuberculosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of tuberculosis partnering trends.
 
Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in tuberculosis partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
 
Chapter 3 provides an overview of the leading tuberculosis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active of all bio pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive directory of tuberculosis partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of tuberculosis technologies and products.
 
Report scope
 
Tuberculosis Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to tuberculosis trends and structure of deals entered into by leading companies worldwide.
 
This data driven report includes:
 
  • Trends in tuberculosis dealmaking in the biopharma industry since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • The leading tuberculosis deals by value since 2007
 
In Tuberculosis Partnering 2007-2013, the available deals are listed by:
 
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
 
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Tuberculosis Partnering 2007-2013 provides the reader with the following key benefits:
 
  • In-depth understanding of tuberculosis deal trends since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 130 actual tuberculosis deals entered into by the world’s biopharma companies since 2007
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
TABLE OF CONTENT

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in tuberculosis partnering
2.1. Introduction
2.2. Tuberculosis partnering over the years
2.3. Bigpharma tuberculosis dealmaking activity
2.4. Tuberculosis partnering by deal type
2.5. Tuberculosis partnering industry sector
2.6. Tuberculosis partnering by stage of development
2.7. Tuberculosis partnering by technology type
2.8. Disclosed financial deal terms for tuberculosis partnering
2.8.1 Tuberculosis headline values
2.8.2 Tuberculosis upfront payments
2.8.3 Tuberculosis milestone payments
2.8.4 Tuberculosis royalty rates
 
Chapter 3 – Leading tuberculosis deals
3.1. Introduction
3.2. Top tuberculosis deals by value
3.3. Top tuberculosis deals involving bigpharma
 
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices
 
Appendix 1 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Chart

 
Figure 1: hepatitis partnering since 2007
Figure 2: Bigpharma – top 50 – tuberculosis deals 2007 to 2013
Figure 3: Bigpharma tuberculosis deal frequency – 2007 to 2013
Figure 4: Tuberculosis partnering by deal type since 2007
Figure 5: Tuberculosis partnering by industry sector since 2007
Figure 6: Tuberculosis partnering by stage of development since 2007
Figure 7: Tuberculosis partnering by technology type since 2007
Figure 8: Tuberculosis deals with a headline value
Figure 9: Tuberculosis deals with upfront payment values
Figure 10: Tuberculosis deals with milestone payments
Figure 11: Tuberculosis deals with royalty rates, %
Figure 12: Top tuberculosis deals by value since 2007
Figure 13: Top tuberculosis deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *